Leishmanicidal activity of racemic ± 8-[(4-Amino-1-methylbutyl) amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline

Natural Product Communications

Volumn 5, Issue 3, 2010, Pages 387-390

  Isaac Márquez, Angélica P ^a   McChesney, James D ^b   Dammika Nanayakara, N P ^b   Satoskar, Abhay R ^c   Lezama Dávila, Claudio M ^c  

^a UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

8 aminoquinolines; Chiclero's ulcer; Cutaneous leishmaniasis; Leishmania (L.) mexicana; Leishmanicidal activity

Indexed keywords

8 [(4 AMINO 1 METHYLBUTYL)AMINO] 6 METHOXY 4 METHYL 5 [3,4 DICHLOROPHENOXY]QUINOLINE; ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONATE; UNCLASSIFIED DRUG; 8 ((4 AMINO 1 METHYLBUTYL)AMINO) 6 METHOXY 4 METHYL 5 (3,4 DICHLOROPHENOXY)QUINOLINE; 8-((4-AMINO-1-METHYLBUTYL)AMINO)-6-METHOXY-4-METHYL-5-(3,4-DICHLOROPHENOXY)QUINOLINE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND; QUINOLINE DERIVATIVE;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA MEXICANA; MICROBIAL GROWTH; NONHUMAN; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HELA CELL; LD 50; MOTOR ACTIVITY; ULTRASTRUCTURE;

LEISHMANIA MEXICANA;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; HELA CELLS; HUMANS; LEISHMANIA MEXICANA; LETHAL DOSE 50; MEGLUMINE; MOTOR ACTIVITY; ORGANOMETALLIC COMPOUNDS; QUINOLINES;

EID: 77952522575     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1000500309     Document Type: Article

References (21)

1. Lezama-Dávila CM, Isaac-Márquez AP, editors. (1995) Inmunobiología de las leishmaniosis. México: SEP-UAC.
2. World Health Organization (2009) Leismaniasis: the global trend. http://www.who.int/neglected-diseases/integrated-media-leishmaniasis/en/index. html. Accessed in 14/08/2009.
3. Roberts LJ, Handman E, Foote SJ. (2005) Science, medicine, and the future: Leishmaniasis. British Medical Journal, 321, 801-804.
4. Lezama-Dávila CM, Isaac-Márquez AP, Satoskar AR. (2007) Immunoregulation of chiclero's ulcer. In: Terrazas LI. ed. Advances in the immunobiology of parasitic diseases. India: Research Signpost, 237-252.
5. Lezama-Dávila CM, Isaac-Márquez AP. (2006) Systemic cytokine response in humans with chiclero's ulcers. Parasitology Research, 99, 546-553.
6. Isaac-Márquez AP, Lezama-Dávila CM. (2003) Detection of pathogenic bacteria in skin lesions of patients with chiclero's ulcer. Reluctant response to antimonial treatment. Memórias do Instituto Oswaldo Cruz, 98, 1093-1095.
7. Lezama-Dávila CM, Isaac-Márquez AP, Zamora-Crescencio P, ÚC-Encalada MR, Justiniano-Apolinar SY, Angel-Robles L, Satoskar A, Hernández-Rivero L. (2007) Leishmanicidal activity of Pentalinon andrieuxii. Fitoterapia, 78, 255-257.
8. Werbovetz KA. (2002) Promising therapeutic targets for antileishmanial drugs. Expert Opinion on TherapeuticTargets, 6, 407-422.
9. Croft SL, Sundar S, Fairlamb AH. (2006) Drug resistance in leishmaniasis. Clinical Microbiology Reviews, 19, 111-126.
10. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R. (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. Journal of Biological Chemistry, 279, 31010-31017. (Pubitemid 39037760)
11. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. (2006) Resistance to antimony and treatment failure in human Leishmania (Viana) infection. Journal of Infectious Diseases, 193, 1375-1383.
12. WHO Division of Control of Tropical Diseases (CTD). Leishmaniasis. Http://www.ciesin.org/docs/001-614/001-614.html. Accessed in 15/08/2009.
13. Rocha LG, Almeida JRGS, Macêdo RO, Barbosa-Filho JM. (2005) A review of natural products with antileishmanial activity. Phytomedicine, 12, 514-535.
14. Lezama-Dávila CM, Satoskar AR, Úc-Encalada M, Isaac-Márquez R, Isaac-Márquez AP. (2007) Leishmanicidal activity of artemisinina, deoxoartemisinin, artemether and arteether. Natural Product Communications, 2, 1-4.
15. Kayser O, Kiderlen AF, Croft SL. (2003) Natural products as antiparasitic drugs. Parasitology Research, 90, S55-S62.
16. Nanayakkara NP, Ager AL Jr, Bartlett MS, Yardley V, Croft SL, Khan IA, McChesney JD, Walker LA. (2008) Antiparasitic activities and toxicities of individual enantiomers of the 8-Aminoquinoline 8-[(4-amino-1-methylbutyl)amino]- 6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrobial Agents and Chemotherapy, 52, 2130-2137.
17. Berman JD, Lee LS. (1983) Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. American Journal of Tropical Medicine and Hygiene, 32, 753-759.
18. Kinnamon KE, Steck EA, Loizeaux PS, Hanson WL, Chapman WL Jr, Waits VB. (1978) The antileishmanial activity of lepidines. American Journal of Tropical Medicine and Hygiene, 27, 751-757.
19. Vennerstrom JL, Lovelace JK, Waits VB, Hanson WL, Klayman DL. (1990) Berberine derivatives as antileishmanial drugs. Antimicrobial Agents and Chemotherapy, 34, 918-921.
20. Tekwani BL, Walker LA. (2006) 8-Aminoquinolines: future role as antiprotozoal drugs. Current Opinion in Infectious Diseases, 19, 623-631.
21. McChesney JD, Nanayakkara NP, Bartlett M, Ager AL. (2002) 8-Aminoquinolines. U.S. patent 6,376,511.